bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer
Authors: Weber Peter , Künstner Axel , Hess Julia , Unger Kristian , Marschner Sebastian , Idel Christian , Ribbat-Idel Julika , Baumeister Philipp , Gires Olivier , Walz Christoph , Rietzler Sibylle , Valeanu Laura , Herkommer Timm , Kreutzer Lisa , Klymenko Olena , Drexler Guido , Kirchner Thomas , Maihöfer Cornelius , Ganswindt Ute , Walch Axel , Sterr Michael , Lickert Heiko , Canis Martin , Rades Dirk , Perner Sven , Berriel Diaz Mauricio , Herzig Stefan , Lauber Kirsten , Wollenberg Barbara , Busch Hauke , Belka Claus , Zitzelsberger Horst
Published: April 2023

Supplementary Figure from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer
Supplementary Data from Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Authors: Song Yuqin , Gao Quanli , Zhang Huilai , Fan Lei , Zhou Jianfeng , Zou Dehui , Li Wei , Yang Haiyan , Liu Ting , Wang Quanshun , Lv Fangfang , Guo Haiyi , Zhao Xia , Wang Dan , Zhang Pei , Wang Yidi , Wang Lei , Liu Tengfei , Zhang Yun , Shen Zhirong , Huang Jane , Zhu Jun
Published: April 2023

Supplementary Data from Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Supplementary Data from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer
Authors: Weber Peter , Künstner Axel , Hess Julia , Unger Kristian , Marschner Sebastian , Idel Christian , Ribbat-Idel Julika , Baumeister Philipp , Gires Olivier , Walz Christoph , Rietzler Sibylle , Valeanu Laura , Herkommer Timm , Kreutzer Lisa , Klymenko Olena , Drexler Guido , Kirchner Thomas , Maihöfer Cornelius , Ganswindt Ute , Walch Axel , Sterr Michael , Lickert Heiko , Canis Martin , Rades Dirk , Perner Sven , Berriel Diaz Mauricio , Herzig Stefan , Lauber Kirsten , Wollenberg Barbara , Busch Hauke , Belka Claus , Zitzelsberger Horst
Published: April 2023

Supplementary Data from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer
Supplementary Table 2 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Authors: Fountzilas Christos , Bajor David L. , Mukherjee Sarbajit , Saltzman Joel , Witkiewicz Agnieszka K. , Maguire Orla , Minderman Hans , Nambiar Ram , Rosenheck Hanna R. , Knudsen Erik S. , Muhitch Jason B. , Abrams Scott I. , Wang Chong , Hutson Alan D. , Attwood Kristopher , Hicks Karen A. , Jurcevic Jennifer A. , Kalinski Pawel , Iyer Renuka , Boland Patrick M.
Published: April 2023

Correlate of baseline and on-treatment changes in intratumoral immune cells (flow cytometry) with clinical endpoints (Supplementary Table 2A), immune checkpoint expression by multispectral immunofluorescence in tumor microenvironment (Supplementary Table 2B) and correlation with clinical endpoints (Supplementary Table 2C), immune cells (flow cytometry) in peripheral blood samples at baseline and on treatment (Supplementary Table 2D) and correlation with clinical outcomes (Supplementary Table 2E).
Supplementary Tables from Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance
Authors: Galbo Phillip M. , Zang Xingxing , Zheng Deyou
Published: April 2023

Supplementary Tables S1-S4
Supplementary Figure from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Authors: Kester Lennart , Seinstra Danielle , van Rossum Annelot G.J. , Vennin Claire , Hoogstraat Marlous , van der Velden Daphne , Opdam Mark , van Werkhoven Erik , Hahn Kerstin , Nederlof Iris , Lips Ester H. , Mandjes Ingrid A.M. , van Leeuwen-Stok A. Elise , Canisius Sander , van Tinteren Harm , Imholz Alex L.T. , Portielje Johanneke E.A. , Bos Monique E.M.M. , Bakker Sandra D. , Rutgers Emiel J. , Horlings Hugo M. , Wesseling Jelle , Voest Emile E. , Wessels Lodewyk F.A. , Kok Marleen , Oosterkamp Hendrika M. , van Oudenaarden Alexander , Linn Sabine C. , van Rheenen Jacco
Published: April 2023

Supplementary Figure from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Supplementary Video2 from Whole-body PET Imaging of T-cell Response to Glioblastoma
Authors: Nobashi Tomomi W. , Mayer Aaron T. , Xiao Zunyu , Chan Carmel T. , Chaney Aisling M. , James Michelle L. , Gambhir Sanjiv S.
Published: April 2023

Zr-OX40 DFO-OX40 mAb PET Control, day 5
Supplementary Data from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Authors: Kester Lennart , Seinstra Danielle , van Rossum Annelot G.J. , Vennin Claire , Hoogstraat Marlous , van der Velden Daphne , Opdam Mark , van Werkhoven Erik , Hahn Kerstin , Nederlof Iris , Lips Ester H. , Mandjes Ingrid A.M. , van Leeuwen-Stok A. Elise , Canisius Sander , van Tinteren Harm , Imholz Alex L.T. , Portielje Johanneke E.A. , Bos Monique E.M.M. , Bakker Sandra D. , Rutgers Emiel J. , Horlings Hugo M. , Wesseling Jelle , Voest Emile E. , Wessels Lodewyk F.A. , Kok Marleen , Oosterkamp Hendrika M. , van Oudenaarden Alexander , Linn Sabine C. , van Rheenen Jacco
Published: April 2023

Supplementary Data from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Supplementary Video1 from Whole-body PET Imaging of T-cell Response to Glioblastoma
Authors: Nobashi Tomomi W. , Mayer Aaron T. , Xiao Zunyu , Chan Carmel T. , Chaney Aisling M. , James Michelle L. , Gambhir Sanjiv S.
Published: April 2023

Zr-89 DFO-OX40 mAb PET Vaccinated, day 5
Supplementary Data from Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers
Authors: Harms Kelly L. , Zhao Lili , Johnson Bryan , Wang Xiaoming , Carskadon Shannon , Palanisamy Nallasivam , Rhodes Daniel R. , Mannan Rahul , Vo Josh N. , Choi Jae Eun , Chan May P. , Fullen Douglas R. , Patel Rajiv M. , Siddiqui Javed , Ma Vincent T. , Hrycaj Steven , McLean Scott A. , Hughes Tasha M. , Bichakjian Christopher K. , Tomlins Scott A. , Harms Paul W.
Published: April 2023

Supplementary Materials
Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Chiappori Alberto A. , Creelan Ben , Tanvetyanon Tawee , Gray Jhanelle E. , Haura Eric B. , Thapa Ram , Barlow Margaret L. , Chen Zhihua , Chen Dung Tsa , Beg Amer A. , Boyle Theresa A. , Castro Julio , Morgan Liza , Morris Erick , Aregay Mehreteab , Hurtado Felipe K. , Manenti Luigi , Antonia Scott
Published: April 2023

Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Data from Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers
Authors: Harms Kelly L. , Zhao Lili , Johnson Bryan , Wang Xiaoming , Carskadon Shannon , Palanisamy Nallasivam , Rhodes Daniel R. , Mannan Rahul , Vo Josh N. , Choi Jae Eun , Chan May P. , Fullen Douglas R. , Patel Rajiv M. , Siddiqui Javed , Ma Vincent T. , Hrycaj Steven , McLean Scott A. , Hughes Tasha M. , Bichakjian Christopher K. , Tomlins Scott A. , Harms Paul W.
Published: April 2023

Supplementary Tables
Supplementary Data from A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Authors: Diab Adi , Hamid Omid , Thompson John A. , Ros Willeke , Eskens Ferry A.L.M. , Doi Toshihiko , Hu-Lieskovan Siwen , Klempner Samuel J. , Ganguly Bishu , Fleener Catherine , Wang Xiao , Joh Tenshang , Liao Ken , Salek-Ardakani Shahram , Taylor Carrie Turich , Chou Jeffrey , El-Khoueiry Anthony B.
Published: April 2023

Supplementary Data from A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Authors: Le Xiuning , Sakai Hiroshi , Felip Enriqueta , Veillon Remi , Garassino Marina Chiara , Raskin Jo , Cortot Alexis B. , Viteri Santiago , Mazieres Julien , Smit Egbert F. , Thomas Michael , Iams Wade T. , Cho Byoung Chul , Kim Hye Ryun , Yang James Chih-Hsin , Chen Yuh-Min , Patel Jyoti D. , Bestvina Christine M. , Park Keunchil , Griesinger Frank , Johnson Melissa , Gottfried Maya , Britschgi Christian , Heymach John , Sikoglu Elif , Berghoff Karin , Schumacher Karl-Maria , Bruns Rolf , Otto Gordon , Paik Paul K.
Published: April 2023

Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice